Biotech | September 22, 2022
Charsire's new drug aims to capture dementia treatment market
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Lenalidomide is used to treat various types of cancers.
Despite the technological advancements, there remains no alternative to blood and one unit of blood can save as many as three lives
The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
3D CMOS chip for connecting electroactive tissues and organoids to software
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
Subscribe To Our Newsletter & Stay Updated
